Head-to-head · WeighScore
Blue Sky MD vs NextMeds
The verdict
Blue Sky MD takes it — 67.5/100 to 66.1/100, but only just.
Blue Sky MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blue Sky MD is a LegitScript-certified medical weight-loss practice founded in 2008 with seven North Carolina clinics and telehealth visits available. NextMeds is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Blue Sky MD | NextMeds |
|---|---|---|
| WeighScore | 67.5/100 | 66.1/100 |
| Grade | C | C |
| Scorecard rank | #169 | #207 |
| Semaglutide | $160/mo (starting dose, compounded) | $129/mo (plus a separate fee, compounded) |
| Tirzepatide | $240/mo (starting dose, compounded) | $179/mo (plus a separate fee, compounded) |
| Coverage | 1 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #169 · C
Strengths
- LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
- Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
- Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
- Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
- Insurance accepted in many cases; affordable self-pay options for uninsured patients
Where it loses points
- Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
- Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
- Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
- No explicit lab testing protocol published; online FAQ does not confirm labs are included
- Small regional provider vs. national platforms; limited provider footprint outside North Carolina
Graded #207 · C
Strengths
- Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
- Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
- Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
- Free, no-obligation online assessment before you pay anything
Where it loses points
- Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
- Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
- A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.